Physician profile
Ayeshia Wright
NPI 1215485867
$144,765.00
in general payments reported to CMS, 2019-2025
32 companies · $54K in 2025
The $54K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,941 · 2022: $2,792 · 2023: $28K · 2024: $58K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $33K · Consulting Fee: $12K · Food and Beverage: $11K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,912.07 |
| Travel and Lodging | $32,836.70 |
| Consulting Fee | $12,131.84 |
| Food and Beverage | $10,953.76 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108,865.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $19,807.13 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $10,465.37 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $3,294.62 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $628.49 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $310.01 | 2021-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $107.74 | 2021-2025 | Glassia, Cuvitru |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Insmed, INC. | $96.95 | 2023-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $93.34 | 2023-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $84.21 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Inogen, INC. | $79.06 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen At Home Stationary Concentrator |
| Ani Pharmaceuticals, INC. | $75.64 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $74.26 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $68.82 | 2024-2025 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.66 | 2023-2024 | |
| Advanced Respiratory, INC | $61.33 | 2021 | |
| Lilly USA, LLC | $60.89 | 2025 | Zepbound |
| Viatris Specialty LLC | $54.99 | 2025 | Yupelri |
| Genentech USA, INC. | $48.13 | 2022-2024 | Xolair |
| Merck Sharp & Dohme LLC | $43.67 | 2025 | Winrevair |
| Electromed, INC. | $42.63 | 2023-2024 | Smartvest |
| Phadia US INC. | $42.11 | 2022-2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.99 | 2021-2023 | Jardiance |
| Hikma Pharmaceuticals USA | $30.78 | 2022-2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $28.90 | 2022-2024 | Nuzyra |
| Aytu Biopharma, INC. | $21.48 | 2024 | Karbinal |
| Adma Biomanufacturing LLC | $19.84 | 2024 | |
| Philips North America LLC | $16.75 | 2025 | Vest Therapy Und |
| Pfizer INC. | $15.38 | 2023 | |
| Masimo Corporation | $14.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayeshia Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.